854 related articles for article (PubMed ID: 27581532)
1. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Fournel L; Wu Z; Stadler N; Damotte D; Lococo F; Boulle G; Ségal-Bendirdjian E; Bobbio A; Icard P; Trédaniel J; Alifano M; Forgez P
Cancer Lett; 2019 Nov; 464():5-14. PubMed ID: 31404614
[TBL] [Abstract][Full Text] [Related]
3. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
[TBL] [Abstract][Full Text] [Related]
4. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
6. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
8. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Hu W; Ma Y; Zhao C; Yin S; Hu H
Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
11. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
12. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
[TBL] [Abstract][Full Text] [Related]
13. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
14. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
15. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
16. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
Chen Y; Song W; Gao Y; Dong X; Ji X
Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
[TBL] [Abstract][Full Text] [Related]
17. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR
Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
